

**CALL OF THE EXTRAORDINARY GENERAL SHAREHOLDERS MEETING OF
ONCOMATRYX BIOPHARMA, S.A.**

In Derio (Bizkaia), October 31th, 2025

Dear shareholder:

The extraordinary general shareholders meeting of Oncomatryx Biopharma, S.A. (the "**Company**") is hereby called to be held on December 2nd, 2025, at 11:00 a.m., at the registered office, that is, in Derio (Bizkaia), Parque Tecnológico de Vizcaya, 801-B- 2º, notwithstanding the possibility of both physical attendance at the registered office itself and attendance by telematic means pursuant to the provisions of the Spanish Companies Act (*Ley de Sociedades de Capital*) and Article 15 of the Company's bylaws, under the following:

AGENDA

- First. -** General information on the development of the Company.

- Second.-** Share capital increase through cash contributions, with recognition of pre-emptive subscription right, for a total par value amount of up to nine hundred twenty-two thousand two hundred six euros and sixty cents (€922,206.60€), with express provision for incomplete subscription and through the issuance of up to three million seventy-four thousand twenty-two (3,074,022) new shares of the same class and series as the current ones. Delegation to the members of the board of directors to set the conditions for the share capital increase in all matters not provided for in this resolution, pursuant to the provisions of article 297.1(a) of the Spanish Companies Act, as well as to redraft article 6 of the Company's bylaws.

- Third. -** Authorization granted by the General Shareholders Meeting authorizing the board of directors to proceed with the derivative acquisition of treasury shares, in accordance with article 146 of the Spanish Companies Act.

- Fourth. -** Approval of the remuneration of the managing director (*consejero delegado*), under the terms approved by the ordinary general meeting of June 30th, 2025.

Fifth. - Replacement of Inmoferro, S.L. by Explotaciones Agrícolas Las Pueblas, S.L. as member of the board of directors of the Company.

Sixth. - Delegation of powers.

Seventh. - Drafting, reading and, if any, approval of the minutes of the meeting.

Right to information. Shareholders have the right to examine at the registered office, located in Derio (Bizkaia), Parque Tecnológico de Vizcaya, 801-B-2º (post code 48160) or request the delivery or free dispatch of a copy (which may be sent by email with acknowledgement of receipt if the shareholder accepts this means) of the following documents:

1. Full text of the proposed resolutions corresponding to the items on the agenda, submitted by the Board of Directors; and
2. The proposed resolution relating to the proposed share capital increase and the report of the Board of Directors on the proposed share capital increase proposal under item two of the agenda.

Similarly, in accordance with the provisions of article 197 of the Spanish Companies Act, until the seventh day prior to the day scheduled for the holding of the general meeting, shareholders may request from the board of directors the information or clarifications they deem necessary regarding the matters included in the agenda or to ask in writing the questions they consider as appropriate.

During the holding of the general meeting, the shareholders of the Company may verbally request the information or clarifications they deem appropriate regarding the matters included in the agenda.

Right to include items on the agenda. In accordance with the provisions of article 15 of the Company's bylaws and article 172 of the Spanish Companies Act, shares representing at least 5% of the share capital may request publication of a supplement to the call for the general shareholders' meeting to be published by including one or more items on the agenda.

The exercise of this right must be done through a irrefutable notification which must be received at the registered office within 5 days following the publication of the call. The supplement to the call must be published at least 15 days before the date set for the meeting of the general meeting.

Right of attendance. In accordance with the provisions of article 19 of the Company's bylaws, shareholders whose shares are registered in the shareholder registry book (*libro registro de acciones nominativas*) 5 days prior to the date on which the general meeting is to be held and shareholders who can prove by means of a public document that they have legally acquired their shares from the person listed as the owner in the ledger of registered shares shall be entitled to participate with voice and vote.

Telematic attendance. In accordance with the provisions of article 15 of the Company's bylaws, telematic attendance at the General Shareholders' Meeting will be possible via videoconference. As a result, all shareholders will be sent the *link* to access the meeting through an individual communication to the e-mails included in the Company's databases. In the event that any shareholder wishes to be sent the *link* to another email, they must express this and contact the Company by the following e-mail shareholders@oncomatryx.com, including proof of their status as a shareholder, at least 5 days before the date of the meeting.

Shareholders who wish to attend the General Shareholders' Meeting through telematic means may participate and cast their vote in the same way, in accordance with the following specifications and instructions:

- The videoconference will be held using the Microsoft Teams platform which allows telematic attendance of all shareholders who wish to do so.
- To access the videoconference, it will be necessary to download the Microsoft Teams platform on the computer, mobile phone or other electronic devices having a webcam and audio.
- Prior to the videoconference, an internet link will be provided to join the meeting, via email.

Right of representation. In accordance with the provisions of article 19 of the Company's bylaws, any shareholder who has the right to attend may be represented by another person, even if he or she is not a shareholder. Representation must be granted in writing and on a special basis for each general shareholders' meeting. Any shareholder may exercise his or her right of representation through the proxy card, a template of which will be available on the Company's website (www.oncomatryx.com) from the date of the call of the General Shareholders' Meeting. The proxy card must be completed and signed by the shareholder, signing the corresponding proxy card. The proxy must be accepted by the shareholder's representative, without which it cannot be exercised. To this end, the representative

must also sign the proxy card. The representative to whom the proxy is conferred must exercise it by personally attendance to the General Shareholders' Meeting, handing in the proxy card, at the place and on the day specified for the holding of the General Shareholders' Meeting, at least one hour before the scheduled start time for the meeting. Likewise, proxy cards may be delivered to the registered office, Derio (Bizkaia), Parque Tecnológico de Vizcaya, 801-B- 2º (post code 48160) during the days prior to the General Shareholders' Meeting or they may be sent by the shareholder to the following email address shareholders@oncomatryx.com.

Voting by mail. In accordance with the provisions of article 19 of the Company's bylaws, Shareholders may exercise their voting rights by postal, electronic correspondence or any other means of remote communication. To cast a remote vote, the shareholder must complete and sign the voting card, a template of which will be available on the Company's website (www.oncomatryx.com), indicating his or her votes – in favour or against – abstention or blank vote, marking with a cross in the corresponding box.

The completed and signed card must be sent to Oncomatryx Biopharma, S.A. by postal correspondence to Derio (Bizkaia), Parque Tecnológico de Vizcaya, 801-B-2º (postal code 48160) or by email addressed to the president at the following e-mail shareholders@oncomatryx.com. A shareholder who casts his/her vote by correspondence and does not have a mark in any or all of the boxes intended to indicate the vote on the items of the agenda, will be deemed to have voted in favour of the respective proposals made by the Board of Directors.

The vote card by postal correspondence shall be rendered null and void by subsequent and express revocation by the shareholder, carried out by the same means used to cast the vote and within the term established for this purpose, or by the personal attendance at the General Shareholders' Meeting of the shareholder who has cast the vote by postal correspondence or by the attendance of his or her representative.

The vote card by mail must be received by the Company before 11:59 p.m. on the day before the General Shareholders' Meeting is scheduled to be held, i.e. before 11:59 p.m. on December 1th, 2025. Otherwise, the vote shall be deemed not to have been cast. After the aforementioned deadline, only votes cast in person at the General Shareholders' Meeting by the shareholder or by the shareholder's valid representative shall be accepted. Shareholders who cast their votes remotely by postal correspondence shall be considered as present for the purposes of the quorum of the General Shareholders' Meeting.

Proxy and vote in the event of a supplement to the call. If, as a result of the exercise of the right to include new items on the agenda corresponding to shareholders representing at least 5% of the share capital, a supplement to this call is published, shareholders who have delegated their representation or who have cast their vote before the publication of said supplement may:

- (a) Grant the proxy again with the corresponding voting instructions or cast the vote again, regarding all the items on the agenda (including both the initial items and the new items incorporated through the supplement), in which case the proxy granted or the vote cast previously shall be deemed revoked and shall be null and void; or
- (b) Complete the corresponding voting instructions to the initially designated representative (who must be the same representative, so that another representative cannot be appointed) only regarding the new items on the agenda incorporated by means of the supplement, all in accordance with the procedures and methods mentioned in the previous sections and by the same means used in the proxy conferred or the vote originally cast.

In the event that the shareholder cast the remote vote before the publication of the supplement and does not carry out any of the actions indicated under sections (a) and (b) above, it will be understood that he or she abstains regarding said new points.

Derio, October 31th, 2025. For the Board of Directors, the secretary non-director, Mr. Luis Alba Ferré.